

Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Summer 2025 Symposium

Thursday, July 24, 2025 - 8 - 12 pm Eastern

Program Chair - Kathleen Moore, MD
Co-Chair - Paolo Tarantino, MD

Program Description

The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with ADC. Expert led discussions will provide evidence-based perspectives regarding important clinically relevant topics in drug selection, biomarkers, sequencing, and toxicity management. We will also review the future landscape of care and current as well as upcoming clinical trials. This timely and clinically relevant session aims to equip attendees with actionable knowledge that can be immediately applied in oncology practice.

Interactive case vignettes will offer practical guidance on patient selection, therapeutic strategies, and the management of adverse effects associated with ADCs. Additionally, ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of current ADC and novel future therapies will be explored.

Learning Objectives

Following this activity, participants will be better able to:

- **Explain** the development and mechanism of action of antibody-drug conjugates (ADCs) and identify mechanisms of resistance.
- **Discuss** the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
- **Recognize** and **Manage** adverse events associated with ADC therapy.

Target Audience

This symposium is intended for a broad oncology-focused audience, including members and non-members. Participants may include physicians, research staff, early-career investigators, clinical research associates, basic scientists, medical physicists, clinical trial nurses, patient advocates, and other healthcare professionals involved in cancer treatment and research.

Continuing Education

This symposium is approved to earn **4 AMA PRA Category 1 credits**.

[See agenda for more information on presentations/speakers.](#)

Register now at:

<https://www.nrgoncology.org/Summer2025Mtg/Register>

Sponsored by the NRG Oncology and the GOG Foundation

